HIGHLIGHTS
- who: Yue Chen from the Department of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China, Department of Medical have published the paper: Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma, in the Journal: (JOURNAL)
- what: The aim of this review is to focus on the current knowledge of ICI monotherapy or in combination with other ICIs or molecularly targeted therapies (TKIs or anti-VEGFs) in advanced HCC and to provide an outlook on future prospects. presentation and a high prevalence of liver dysfunction. At the 2017 American Society of Clinical Oncology (ASCO) annual . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.